If you're looking for the Minnesota Organization on Fetal Alcohol Syndrome (MOFAS) you have come to the right place. We have some exciting news about our organization. We have a new name! MOFAS has officially been renamed Proof Alliance. Our mission remains the same: to prevent prenatal alcohol exposure and to improve the quality of life for people living with fetal alcohol spectrum disorders (FASD).
We now have the proof that prenatal alcohol exposure is a leading cause of brain injury in children. We have the proof that FASD is 100% preventable and people living with an FASD can reach 100% of their potential.
We seek to build powerful alliances with people with an FASD, their families, legislators, experts in the field, new partners, and community members to bring awareness, research, and services to this field.
Proof Alliance is rebranding, expanding, and we're moving! We have a new logo, website, and prevention campaign to help change the norms around drinking during pregnancy. And in May 2019 we will be moving to a stand-alone building. Proof Alliance commits to the people of Minnesota and we will continue to develop transformative programs to help Minnesotans impacted by FASD.
University of Minnesota pediatric neuropsychologist Jeff Wozniak and neonatologist Michael Georgieff have earned a three-year $675,000 grant from the National Institutes of Health to study children affected by prenatal alcohol exposure.
The latest NIH grant will allow Wozniak, Georgieff and colleagues to continue their study of a novel treatment for brain development in two to five year-old children with Fetal Alcohol Spectrum Disorders.
Wozniak, an associate professor in the Medical School’s Department of Psychiatry, says that the first-ever study of this non-drug treatment in FASD will test its efficacy in permanently enhancing learning and memory in children who have suffered brain damage as a result of prenatal alcohol exposure. The world-class resources provided by the University’s Center for Neurobehavioral Development, directed by Georgieff, and the University’s Clinical and Translational Science Institute, make the study possible. Co-investigators from the University include: Maria Kroupina, Judith Eckerle, Neely Miller, and Ann Brearley.